MYCN and neuroblastoma: Although EDF1 expression hardly exhibited statistical differences in the risk and stage of MNB tumors (Fig. S3A, S3B), we observed a significant up-regulation of EDF1 levels in NB patients with high-risk, advanced stage, MYCN amplification, and progression (Fig. S3D), accompanied by lower OS and EFS (GSE49710) (Fig. S3C).